Scorpius Holdings Inc., an integrated biomanufacturing company, has announced a strategic partnership with a US-based biotech company. Under this agreement, the biotech company will work with Scorpius’ program management team to transfer a research cell bank (RCB) to Scorpius’ facilities in San Antonio, TX for future biomanufacturing activities.
 
“This partnership underscores Scorpius’ ability to support biotech companies at every stage of their journey, from innovative research to clinical trials,” said Jeff Wolf, CEO of Scorpius. “We are seeing a growing number of biotech companies seeking U.S.-based biomanufacturing partners, and Scorpius is equipped to provide early-stage development, preclinical manufacturing, and cGMP clinical manufacturing for both mammalian and microbial programs.”
 
Wolf added, “Our clients highlight our flexibility and responsiveness—qualities often lacking in larger multinational CDMOs. With this partnership, we continue to fulfill the critical need for secure, U.S.-based development and manufacturing support for groundbreaking biologics research.”
 
Wolf recently released a letter to shareholders in which he provides a corporate update.